Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: DZNep promotes mouse bone defect healing via enhancing both osteogenesis and osteoclastogenesis

Fig. 1

DZNep promoted RANKL-induced osteoclastogenesis without cytotoxic effects in vitro. A The structure of DZNep. B Cell viability of DZNep-treated BMMs was tested by CCK-8 at 24, 48, and 96 h. C IC50 value obtained for the activity of DZNep against BMMs. D BMMs were treated with different concentrations of DZNep and stimulated by M-CSF (30 ng/ml) and RANKL (50 ng/ml) for 5 days. Then the cells were fixed with 4% paraformaldehyde and stained for TRAP. Scale bar = 100 μm. E Quantification of TRAP-positive multinuclear cells, number of osteoclasts, area of osteoclasts, and osteoclast size (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). F TRAP-positive BMMs following the treatment with 25 nM DZNep for indicated days during osteoclastogenesis. Scale bar = 100 μm. G Quantification of TRAP-positive multinuclear cells, number of osteoclasts, area of osteoclasts, and osteoclast size (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are expressed as median and interquartile range, n = 4–6

Back to article page